FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
This article was originally published in The Pink Sheet Daily
Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.
You may also be interested in...
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
FDA budget challenges, biosimilars, R&D revamps and social media are among stories from the past year that captured the attention of readers and reflect major biopharma trends.